Emmanuel S. Antonarakis, MBBCh

Articles

Dr. Antonarakis on Trial Examining Sipuleucel-T Plus Radium-223 in Bone-Metastatic CRPC

April 9th 2020

Emmanuel S. Antonarakis, MBBCh, discusses the design of a randomized phase II study of sipuleucel-T with or without radium-223 dichloride in men with asymptomatic bone-metastatic castrate-resistant prostate cancer.

Dr. Antonarakis on the Utility of Sipuleucel-T Plus Radium-223 in Nonmetastatic CRPC

March 31st 2020

Emmanuel S. Antonarakis, MBBCh, discusses the utility of sipuleucel-T plus radium-223 in nonmetastatic castration-resistant prostate cancer.

Dr. Antonarakis on PD-1/PD-L1 Monotherapy in Prostate Cancer

March 28th 2020

Emmanuel S. Antonarakis, MBBCh, discusses the optimal use of PD-1/PD-L1 monotherapy in prostate cancer.

Dr. Antonarakis on Updated Analysis of the KEYNOTE-199 Trial in mCRPC

March 13th 2020

Emmanuel S. Antonarakis, MBBCh, discusses updated data from the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

Dr. Antonarakis on Sipuleucel-T Plus Radium-223 in Bone-Metastatic CRPC

February 15th 2020

Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses a phase II trial evaluating the combination of sipuleucel-T (Provenge) plus radium-223 dichloride (Xofigo) versus sipuleucel-T alone in patients with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).

Dr. Antonarakis on Galeterone for Prostate Cancer

December 17th 2015

Emmanuel Antonarakis, MBBCh, associate professor of Oncology, associate professor of Urology at Johns Hopkins Medicine, discusses the use of galeterone in prostate cancer.

Dr. Emmanuel Antonarakis on AR-V7 and Response to Taxanes in mCRPC

February 27th 2015

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses a study looking at androgen receptor splice variant 7 (AR-V7) in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Antonarakis on AR-V7 and Resistance to AR-Targeting Agents in mCRPC

October 8th 2014

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses AR-V7 and resistance to AR-targeting agents in men with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Antonarakis on Sequencing ADT and Sipuleucel-T

March 7th 2013

Emmanuel Stylianos Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses a phase II trial evaluating the optimal sequence for sipuleucel-T and ADT in patients with biochemically recurrent prostate cancer.

Dr. Antonarakis Describes the TAXYNERGY Trial in mCRPC

February 25th 2013

Emmanuel Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the TAXYNERGY trial that is exploring molecular markers of response in men with mCRPC following an early switch in taxane-based treatment.